Pivotal Therapeutics (OTCMKTS:PVTTF – Get Free Report) and Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
Analyst Ratings
This is a summary of current ratings for Pivotal Therapeutics and Centessa Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pivotal Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Centessa Pharmaceuticals | 1 | 9 | 4 | 0 | 2.21 |
Centessa Pharmaceuticals has a consensus price target of $41.33, indicating a potential upside of 3.28%. Given Centessa Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Pivotal Therapeutics.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pivotal Therapeutics | N/A | N/A | N/A | N/A | N/A |
| Centessa Pharmaceuticals | $15.00 million | 412.63 | -$197.53 million | ($1.79) | -22.36 |
Pivotal Therapeutics has higher earnings, but lower revenue than Centessa Pharmaceuticals.
Institutional & Insider Ownership
82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Pivotal Therapeutics and Centessa Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pivotal Therapeutics | N/A | N/A | N/A |
| Centessa Pharmaceuticals | N/A | -60.37% | -44.17% |
Summary
Centessa Pharmaceuticals beats Pivotal Therapeutics on 6 of the 8 factors compared between the two stocks.
About Pivotal Therapeutics
Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Receive News & Ratings for Pivotal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pivotal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
